Glaukos Corp (GKOS)vsMerck & Company Inc (MRK)
GKOS
Glaukos Corp
$159.86
-1.03%
HEALTHCARE · Cap: $9.66B
MRK
Merck & Company Inc
$150.91
+0.94%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10762% more annual revenue ($66.57B vs $612.84M). MRK leads profitability with a 4.8% profit margin vs -30.7%. GKOS appears more attractively valued with a PEG of 1.64. GKOS earns a higher WallStSmart Score of 44/100 (D).
GKOS
Hold44
out of 100
Grade: D
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.6%
Fair Value
$119.32
Current Price
$159.86
$40.54 discount
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$150.91
$67.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 49.5% year-over-year
Earnings expanding 1896.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 13.8x book value
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Trading at 8.9x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 49.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
GKOS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
GKOS carries more volatility with a beta of 0.77 — expect wider price swings.
GKOS is growing revenue faster at 49.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
GKOS scores higher overall (44/100 vs 36/100) and 49.5% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?